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The FACET (Formoterol and Corticosteroid Establishing Therapy) study established that there is a clear clinical
benefit in adding formoterol to budesonide therapy in patients who have persistent symptoms of asthma despite
treatment with low to moderate doses of an inhaled corticosteroid. We combined the clinical results from the
FACET study with an expert survey on average resource use in connection with mild and severe asthma
exacerbations in the U.K., Sweden and Spain. The primary objective of this study was to assess the health
economics of adding the inhaled long-acting b2-agonist formoterol to the inhaled corticosteroid budesonide in the
treatment of asthma.
The extra costs of adding the inhaled b2-agonist formoterol to the corticosteroid budesonide in asthmatic
patients in Sweden were offset by savings from reduced use of resources for exacerbations. For Spain the picture
was mixed. Adding formoterol to low dose budesonide generated savings, whereas for moderate doses of
budesonide about 75% of the extra formoterol costs could be recouped. In the U.K., other savings offset about half
of the extra cost of formoterol. All cost-effectiveness ratios are within accepted cost-effectiveness ranges reported
from previous studies. If productivity losses were included, there were net savings in all three countries, ranging
from Euro 267–1183 per patient per year.
In conclusion, adding the inhaled, long-acting b2-agonist formoterol to low–moderate doses of the inhaled
corticosteroid budesonide generated significant gains in all outcome measures with partial or complete offset of
costs. Adding formoterol to budesonide can thus be considered to be cost-effective.
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Recent years have seen healthcare resources increasingly
constrained, mainly due to a growing demand for health
care. In line with this, third-party payers are now generally
requesting evidence of ‘value for money’ when new
treatments are introduced and funded. New therapies not
only require assessments for ecacy and safety, but now
also from a cost-effectiveness point of view (1).Received 18 October 2000 and accepted in revised form 12 March
2001.
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0954-6111/01/060505+08 $35?00/0The FACET (Formoterol and Corticosteroid Establish-
ing Therapy) study was conducted to assess the role of the
long-acting, inhaled b2-agonist formoterol (Oxis
1 Turbu-
haler1) in treating patients with moderate, persistent
asthma (2). The double-blind, 1-year study assessed the
effects of adding inhaled formoterol to both a low and a
moderate dose of the inhaled corticosteroid budesonide
(Pulmicort1 Turbuhaler1). The rates of mild and severe
exacerbations were reduced significantly by adding for-
moterol. The FACET study established that there is clear
clinical benefit in adding formoterol to budesonide therapy
in patients who have persistent symptoms of asthma despite
treatment with low to moderate doses of an inhaled
corticosteroid.
The primary objective of the present study was to assess
the health economic value of adding formoterol to
budesonide in the treatment of moderate, persistent# 2001 HARCOURT PUBLISHERS LTD
506 F. ANDERSSON ET AL.asthma. Thus, we compared the different treatment
strategies in the FACET study.
Materials and methods
THE FACET STUDY
The FACET study examined the clinical ecacy and the
safety of adding formoterol to budesonide over a 12-month
period (2). The study was carried out in nine countries.
During the 4-week run-in period, patients received inhaled
budesonide at a dose of 800 mg twice daily to stabilize their
asthma. A total of 852 patients, aged 18–70 years, who had
had asthma for at least 6 months, had been treated with an
inhaled corticosteroid for at least 3 months, had a daily pre-
run in corticosteroid dose of less than 1600 mg(beclometha-
sone, budesonide pressurized metered-dose inhaler) or
800 mg (budesonide Turbuhaler1 or fluticasone), and
successfully completed the run-in period, were randomized
to one of four treatment groups:
. Low-dose budesonide (total daily dose 200 mg) plus
placebo
. Low-dose budesonide plus formoterol (total daily dose
24 mg)
. Moderate-dose budesonide (total daily dose 800 mg)
plus placebo
. Moderate-dose budesonide plus formoterol (total
daily dose 24 mg)
Of the randomized patients, 81% completed the study.
Patients were withdrawn if they had three severe exacerba-
tions within 3 months or five during the 12-month period.
This included 10 patients in the low-dose budesonide arm,
seven in the low-dose combination arm, four in the
moderate-dose budesonide arm, and none in the moder-
ate-dose combination arm. The main reasons for not
completing the study were, for example, incorrect rando-
mization, non-compliance with study procedures, adverse
events, and being lost to follow-up.
The primary outcome studied was the incidence of mild
and severe exacerbations of asthma. A mild exacerbation
was defined as 2 consecutive days with any combination of
the following:
. A peak expiratory flow (PEF) in the morning that was
more than 20% below the baseline value
. The use of more than three additional inhalations of
terbutaline per 24 h as compared with the baseline
period
. Awakening at night due to asthma.
A severe exacerbation was defined as:
. Requiring treatment with oral glucocorticoids, as
judged by the investigator, and/or
. A decrease in PEF as measured in the morning, on 2
consecutive days, of more than 30% below the
baseline value.
The rates of mild and severe exacerbations were reduced
by 40 and 26%, respectively, when formoterol was added tobudesonide. The clinical results were tested for homogene-
ity across study centres.
THE ECONOMIC ANALYSIS
The analysis combined the outcome data from the FACET
study with an expert survey. The purpose of the survey was
to obtain complementary estimates of average resource
utilization in connection with a mild and severe exacerba-
tion, respectively.
The perspective of the economic analysis was that of
society, and the countries included were Sweden, U.K. and
Spain. (The FACET study included 126 patients from the
U.K. and 107 from Spain. Sweden did not participate.)
These countries were selected because they represent
Northern, Central and Southern Europe, and hence may
be reasonably representative of other countries in these
regions in terms of treatment patterns and relative prices.
The primary analysis encompassed direct medical costs
(drugs, physician visits, emergency visits, etc.) only, since
we judged physicians to be slightly less capable of
estimating patients’ absence from work than their use of
healthcare resources.
The sample comprised 17–18 physicians in each of the
three countries. They consisted of physicians who were
specialists in pulmonary medicine (seven or eight per
country) or who were general practitioners (10 per
country), and who were interviewed individually, face-to-
face, by an independent, trained nurse from a company
specializing in conducting surveys. The interviews took
between 45 and 60 min. The physicians were recruited from
a database of experts who had participated in previous
surveys, by calling hospitals in selected locations, or at
random from the ocial country lists of physicians. The
physicians provided wide geographical representation but
were mainly from the largest urban areas in each country.
A questionnaire was developed, and following a pilot test
it was sent to the physicians, together with information on
the purpose of the survey, a few days before the interview.
Before being accepted in the survey the physicians had to
fill in and return a screening questionnaire which included
questions on speciality (GP or specialist), age (to exclude
retired physicians), and the number of asthma patients
treated per month (to include physicians with day-to-day
contacts with asthmatics). The physicians were asked to
estimate average resource use for a FACET-like patient in
connection with a mild or severe asthma exacerbation (as
defined in the FACET study).
The expert group mean estimates were combined with
FACET data (medication, hospitalization) and average
prices from ocial price lists* in order to calculate the cost
of a mild and a severe exacerbation in each country.
Examples of direct costs included costs of physician visits,
emergency visits and hospital stays, in connection with the
exacerbations. Indirect costs included the cost of absence
from work in connection with an exacerbation, adjusted for
*A list of sources is available from the authors upon request.
COST-EFFECTIVENESS OF ADDING FORMOTEROL 507employment rates. The cost estimates for the two types of
exacerbations were then related to individual, per patient
incidence data from the study.
Information on the use of budesonide, formoterol, other
medication and hospitalizations was prospectively recorded
during the course of the FACET study. This was the basis
for the largest part of the costs.
The clinical outcomes from the FACET study and the
costs incurred were calculated per patient-year (3).
All costs were expressed as Euros at 1999 values. Earlier
values were updated to 1999 values using the local
consumer price index. The exchange rates for one Euro
were GBP 0?61, SEK 8?39 and ESP 166?39 in September
2000.
OUTCOME VARIABLES
The FACET study had a number of clinical outcome
measures, including exacerbations avoided and symptom-
or episode-free days gained, so we conducted a cost-
consequence study, i.e. a study presenting costs in relation
to the specific outcomes (4). When costs were larger in the
combination group we calculated an incremental cost-
effectiveness ratio, relating the extra costs to the extra gains
in symptom-free days (SFDs).
Exacerbations, episode-free days (EFDs) and symptom-
free days were used in the health economics analysis. An
episode-free day was defined as a day that satisfied all of the
following criteria: morning PEF 480% of baseline, no
inhalation of a b2-agonist, no asthma symptoms, no
awakenings at night due to asthma and no adverse events.
A symptom-free day was defined as a day with no
symptoms.
SENSITIVITY ANALYSIS
It has been recommended that health economic results be
presented both with and without indirect costs (5). Thus, in
the first sensitivity analysis we studied total costs, including
indirect costs. The physician panels in each country
estimated likely absence from work in connection with a
mild or severe exacerbation.
In the second sensitivity analysis we determined the
percentage by which the physicians’ estimates of costs for a
mild and a severe exacerbation would have to be changed to
reverse the results. This threshold analysis was done to take
into account the variation among the costs of exacerbations
and is a rather demanding way of validating the results in
that the estimates of both mild and severe exacerbations are
being altered in the same direction at the same time.
STATISTICAL ANALYSIS
We used the Student’s t-test to test for differences between
groups. The Student’s t-test is based on the assumption that
the underlying distributions of the two samples are normal
(Gaussian), and have a common variance. The test is fairly
robust regarding violations of the assumptions, at least with
larger sample sizes (6). The 95% confidence intervals for thecost of exacerbations were estimated using bootstrap and
Efrons percentile method.
Results
THE COST OF AN EXACERBATION
The resources used in connection with a mild and a severe
exacerbation, the frequency of utilization of the resources,
and the unit cost of each resource are listed in Table 1.
There were some country-specific differences in how
patients were treated, such as in the use of GPs or asthma
specialists for example. To some extent the resource use in
connection with an exacerbation was complementary, e.g.
visits to a specialist instead of a GP (Sweden/Spain vs.
U.K.), or emergency visits instead of GP visits (Sweden/
Spain vs. U.K.). As a result of these differences, but mainly
because of the differences in unit costs, the U.K. exacer-
bation estimates are only about 60–80% as high as the
Swedish estimates.
OUTCOMES
The outcome measures in the health economic analysis are
presented in Table 2. All outcomes improved significantly
when formoterol was added, with the best results for the
moderate-dose budesonide plus formoterol arm.
COSTS
A detailed comparison of the costs for the four treatment
strategies is presented in Table 3. The cost of adding
formoterol was generally offset by a reduction in the use of
other resource items, primarily in association with frequent
mild exacerbations (the main cost-driver was GP visits),
thus generating cost savings in Sweden, and cost-savings for
low dose budesonide in Spain. For the U.K. the reduction
in direct costs did not completely counterbalance the cost of
adding formoterol, but between 45–61% of the extra cost of
formoterol could be offset. This resulted in an incremental
cost of Euro 4?67 and 6?60 per SFD gained. In Spain, 78%
of the extra cost of adding formoterol to a moderate dose of
budesonide could be offset, thus resulting in a cost per SFD
of Euro 2?51.
The cost offsets were larger in all three countries when
adding formoterol to the low dose of budesonide. However,
in all three countries the combination of the moderate dose
of budesonide and formoterol was the most cost-effective
alternative.
SENSITIVITY ANALYSIS
When productivity losses were included in the analysis (FIG.
1), adding formoterol generated cost savings in all three
countries. This cost saving was statistically significant in
Sweden when formoterol was added to the low dose of
budesonide.
TABLE 1: The estimated resource use and cost per mild and severe exacerbation (1999 values).
UK Sweden Spain
Resources Unit cost Estimated percentage of
all patients who would
require the resource
Unit cost Estimated percentage
of all patients who
would require the resource
Unit cost Estimated percen-
tage of all patients
who would require
the resource
(GBP) Mild Severe (SEK) Mild Severe (PES) Mild Severe
Visit to a GP 17?28 35?9 69?1 790 29?4 56?9 6909 66?2 31?1
Visit to a specialist 70?18 2?4 7?7 1491 9?4 28?1 8997 22?0 27?2
Visit to a nurse 6?48 20?1 27?2 339 9?7 18?3 2322 0?1 0?6
House-call by physician 50?75 2?2 22?1 790 1?8 6?7 3467 4?2 16?5
House-call by nurse 15?20 0?6 2?9 339 2?2 2?2 2534 0 0
Phone-call to physician 9?29 5?4 12?4 110 30?3 49?4 1210 5?1 13?2
Phone-call to nurse 1?44 5?8 7?3 34 24?5 26?2 1120 0?4 0
Emergency unit visit 38?70 2?2 20?5 2794 9?5 31?1 16 300 6?0 44?2
Admission to hospital*
(ambulance)
170?67 0 7?0 2479 0 7?0 2317 0 30?6
Days in hospital* 181 0 7?4 3599 0 7?4 32 005 0 7?4
% employed — 82?6 56?6 — 65?8 43?2 — 54?2 42?3
% absence from work 21?6 72?5 20?4 82?4 16?8 75?8
Days absent from work 75?81 3?0 7?6 1133 2?6 7?1 12 715 3?9 10?8
Total cost{ 57 377 1228 6712 19 213 84 749
[27; 96] [321; 432] [798; 1655] [5674; 7782] [8151; 37 395] [64 631; 110 521]
(Euro) (93) (615) (146) (800) (109) (509)
Of which direct costs 12 146 735 3973 7743 29 380
[8; 16] [139; 155] [463; 1028] [3602; 4371] [5374; 9946] [26 625; 32 272]
(Euro) (20) (238) (88) (474) (46) (177)
Of which indirect costs 45 230 493 2739 11 470 55 369
[17; 84] [173; 285] [201; 876] [1815; 3864] [1954; 27 504] [34 760; 81 923]
(Euro) (73) (375) (59) (326) (69) (332)
Example: For the U.K., on average 2?4% of all FACET-like patients visit a specialist when having a mild exacerbation and close to 8% visit a specialist when having a
severe exacerbation. For Sweden, the percentages are about 9 and 28 and for Spain 22 and 27, respectively. Percentages are the group means.
Sources of unit costs available from the authors on request.
Exchange rates as of September 2000: 1 Euro=GBP 0?613, SEK 8?39, PES 166?386.
*Collected within the FACET trial.
{95% confidence interval within brackets.
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TABLE 2. Average per-patient outcomes over 12 months, utilizing a per patient-year approach
Groups
Outcomes Budesonide
200 mg only
Formeterol
24 mg added
Gains from
adding formo-
terol
Budesonide
800 mg only
Formeterol
24 mg added
Gains from
adding formo-
terol
Number of mild
exacerbations
19?5 11?6 7?9 (14?1)*** 13?6 7?9 5?7 (8?9)**
Number of severe
exacerbations
1?8 1?3 0?5 (0?2)** 0?9 0?5 0?4 (0?1)**
Number of symptom-free days 209 247 38** 222 263 41**
Number of episode-free days 152 186 34** 167 200 33*
The values in brackets are the outcomes presented in the clinical publication, calculated according to intention to treat (3).
P-values: *P50?05; **P50?01; ***P50?001.
TABLE 3. Annual per-patient health care costs and savings after adding formoterol to budesonide, compared to budesonide
alone (Euro, 1999 values)
UK Sweden Spain
Budesonide
200+Formo-
terol vs. Bude-
sonide 200
Budesonide
800+Formo-
terol vs. Bude-
sonide 800
Budesonide
200+Formo-
terol vs. Bude-
sonide 200
Budesonide
800+Formo-
terol vs. Bude-
sonide 800
Budesonide
200+Formo-
terol vs. Bude-
sonide 200
Budesonide
800+Formo-
terol vs. Bude-
sonide 800
Formoterol 493 493 405 405 443 443
Other medication 724 721 715 714 711 79
Mild asthma exacerbations 7152 7109 7690 7497 7367 7264
Severe asthma exacerbations 7126 791 7248 7180 793 767
Net cost difference 191 271*** 7549 7286 728 103
Total direct costs in Euro 1159 vs. 968 1218 vs. 947 2161 vs. 2710 1638 vs. 1924 1310 vs. 1336 1143 vs. 1040
Total direct costs in local
currency
711 vs. 593 747 vs. 581 18 131 vs.
22 738
13 741 vs.
16 141
217 902 vs.
222 317
190 207 vs.
173 074
Incremental cost per SFD
(Euro)
4?67 6?60 Not relevant
(dominant)
Not relevant
(dominant)
Not relevant
(dominant)
2?51
***P50?001.
COST-EFFECTIVENESS OF ADDING FORMOTEROL 509The second sensitivity analysis showed that the direct
costs of exacerbations would need to increase by 69% (low
dose budesonide plus formoterol) and 135% (moderate
dose budesonide plus formoterol) respectively, over the
estimates provided by the experts for the formoterol costs
to be completely recouped in the U.K. In Sweden the
exacerbation costs would need to be reduced by 58% and
41%, respectively, to reverse the outcome (i.e. negate the
cost savings). To reverse the outcome in Spain, the cost
estimates for low-dose budesonide and moderate-dosebudesonide would need to decrease by 6% or increase by
31%, respectively.
Discussion
The extra direct costs of adding the long-acting inhaled b2-
agonist formoterol to the corticosteroid budesonide in
asthmatic patients were generally offset by less resource use
due to fewer exacerbations. In Sweden and Spain (low-dose
FIG. 1. (a) Annual total costs per patient—200 mg budesonide. (b) Annual total costs per patient—800 mg budesonide.
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COST-EFFECTIVENESS OF ADDING FORMOTEROL 511budesonide) the extra cost of adding formoterol was more
than offset. In the U.K. and in Spain (high-dose budeso-
nide), the extra cost of formoterol was only partially offset.
The net costs need to be considered in relation to the
significant gains in the various clinical outcome measures
found in the FACET study. If indirect costs are included,
adding formoterol generates a potential for net savings. The
most cost-effective strategy in the FACET study was the
moderate dose of budesonide combined with formoterol.
Few health economic studies have previously looked at
long-acting b2-agonists, and none have investigated the
cost-effectiveness of adding a long-acting b2-agonist to a
corticosteroid. Rutten-van Mo¨lken et al. (7) examined the
cost-effectiveness of adding a corticosteroid or an anti-
cholinergic to a short-acting b2-agonist in patients with
moderately severe obstructive airway disease. They found
that anti-cholinergics were not cost-effective whereas
inhaled corticosteroids, at a cost of about US$5 per
symptom-free day, were considered to be cost-effective.
Rutten-van Mo¨lken et al. and Campbell et al. (8,9)
compared two long-acting b2-agonists, formoterol and
salmeterol. Whereas Rutten-van Mo¨lken et al. found no
difference in cost-effectiveness, Campbell et al. found that
formoterol (supplied with a different device than in the
previous study) patients were significantly less expensive
and that there was a positive trend in SFDs.
When assessing cost-effectiveness, the ideal is to conduct
a prospective study. Information on resource use would
then be collected at the same time as the clinical outcomes.
As we did not know the frequency of visits to physicians
and nurses, other health care contacts, emergency unit visits
and absence from work in relation to an exacerbation in the
FACET study, we complemented the information we had
with expert estimates of likely resource use. This is an
accepted method within the health economic community,
but only when no other options exist (10). Another
possibility for carrying out a retrospective analysis could
be to conduct a patient chart review. In the present case,
however, this was not possible, since an asthma exacerba-
tion is largely a matter of clinical definition based on use of
rescue medication, symptoms and PEF values. Valid and
complete data concerning the latter two criteria are most
commonly missing in patient charts. Also, the patient may
not realise that he/she is experiencing an exacerbation. In
the FACET study 18% of those experiencing a fall in PEF
of more than 30% did not take the recommended oral
corticosteroids (11). Furthermore, there is a risk of under-
estimation since some of the resource use may take place
before the patient actually seeks care, e.g. an increased use
of medication and loss in productivity. The effect of severe
exacerbations is usually obvious seven or more days before
the patient seeks medical attention (11).
The number of experts surveyed in each country was
large compared to the average of six surveyed in previous
studies (10). In addition, we tested the validity of the
estimates by conducting demanding threshold analyses. We
also surveyed experts from both primary and secondary
care, thus reflecting real life clinical practice. The majority
of costs (generated from drug consumption and hospitali-
zations) were obtained directly from the clinical study.A limitation of this panel expert approach is that the
expert estimates may not be accurate or may change over
time. Data on the cost of exacerbations is rather sparse. For
the U.K., Hoskins et al. (12) found that the average annual
health care costs per patient who had an asthma attack
were £381 compared with £108 for those who had not had
an asthma attack. However, the number of exacerbations
per year that these patients experienced was not stated, nor
was an asthma attack defined.
International asthma guidelines propose high dose
inhaled corticosteroids as an alternative treatment option
to adding long-acting b2-agonists, for patients not well-
controlled on low to moderate doses of corticosteroids. The
FACET study did not include such a study arm and hence
this option cannot be tested in this analysis. One can only
speculate as to the cost-effectiveness of a high dose of
inhaled corticosteroids compared to adding a long-acting
b2-agonist, but there are indications of a relatively poor
dose–response when increasing from a moderate to a high
dose of corticosteroids (13).
There were major differences between the three countries
in the proportions of patients requiring a particular type of
resource use. We do know that there are variations in
medical practice among countries. Jepson et al. (14)
investigated the prescribing of asthma drugs by GPs in
eight European areas (Belgium, Ireland, England, Italy,
Northern Ireland, Portugal, Scotland and Spain). For adult
asthmatics the use of short-acting b-agonists ranged from
24% in Belgium to 44% in England (Spain 40%), and the
use of long-acting b-agonists ranged from 1% in Ireland to
9% in Italy (England 2%, Spain 9%). As for inhaled
corticosteroids, these were prescribed for only 14% of the
Italian asthmatics but for twice as high a percentage in
Spain, Scotland and England. The use of oral corticoster-
oids ranged from 3% in Portugal to 19% in Northern
Ireland (Spain 4% and England 14%). To some extent the
resource use in connection with an exacerbation was
complementary in our study, with some resources being
used as substitutes for other.
We conducted the analysis in three European countries
with differences in treatment patterns, prices of healthcare
and healthcare organization. The clinical results, including
the consumption of drugs, were pooled across all patients in
the health economic evaluation. Although there were some
local variations in the use of specific resource items, the
results show reasonable consistency in that adding for-
moterol to budesonide is cost-effective in each of these three
countries.
In conclusion, adding the inhaled long-acting b2-agonist
formoterol to low to moderate doses of the inhaled
corticosteroid budesonide generates significant gains in all
core outcome measures, with partial or complete offset of
costs. Adding formoterol to budesonide can thus be
considered to be cost-effective.
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